Spots Global Cancer Trial Database for Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Official Title: Investigate the Real-life Treatment Outcome of Regorafenib in Treating mCRC Patients
Study ID: NCT03829852
Conditions
Interventions
Study Description
Brief Summary: Regorafenib is currently the standard of care for refractory mCRC patients. Pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg dose given once daily. In the clinic, patients often have some complicated condition. This study aims to perform retrospective medical chart review of mCRC patients who received regorafenib treatment in two medical centers in Taiwan to examine treatment effectiveness in the routine clinical practice setting.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Taipei Veterans General Hospital, Taipei, , Taiwan
Contact Details
Name: Hao-Wei Teng, MD, PhD
Affiliation: Taipei Veterans General Hospital, Taiwan
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
